sana-ex104_270.htm



Exhibit 10.4

CONFIDENTIAL

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED

Amendment NO. 6 to
EXCLUSIVE START-UP LICENSE Agreement between
SANA BIOTECHNOLOGY, INC. and UNIVERSITY OF WASHINGTON

THIS AMENDMENT NO. 6 (“Amendment No. 6”), with an effective date as of the date of the last signature (“Amendment No. 6 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).

 

WHEREAS, Cytocardia, Inc. (“Cytocardia”) and University entered into an Exclusive Start-Up License Agreement for [***], with a University Reference [***], dated October 9, 2018 (the “Original Agreement”), and amended on November 6, 2019 (“Amendment No. 1”) and July 16, 2020 (“Amendment No. 2”), 

WHEREAS, Cytocardia assigned the Original Agreement, as amended by Amendment No. 1 and Amendment No. 2, to Company pursuant to that certain Assignment of License Agreement dated as of effective as of November 11, 2020, and pursuant to which Assignment of License Agreement the parties thereto further amended the Original Agreement, as amended by Amendment No.1 and Amendment No. 2 thereto (“Amendment No. 3”);

WHEREAS, Company and University entered into additional amendments amending the Original Agreement (as amended by Amendment No. 1, Amendment No. 2 and Amendment No. 3) on January 21, 2021 (“Amendment No. 4”) and on February 25, 2021 (“Amendment No. 5”) 

WHEREAS, by this Amendment No. 6, the Parties wish to further amend the Original Agreement as amended by Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, and Amendment No. 5, as set forth in Section 2 herein; and

WHEREAS, the Parties desire that all other terms and conditions of the Original Agreement as amended by Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, and Amendment No. 5 remain in full force and effect.

NOW, THEREFORE, COMPANY and UNIVERSITY hereby agree as follows:

1.Capitalized terms used in this Amendment No. 6 shall have the same meaning as those in the Original Agreement, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, and Amendment No. 5 as the case may be, unless specifically defined otherwise in this Amendment No. 6.  All article and section references shall refer to the corresponding Article and Section in the Original Agreement as amended by Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, and Amendment No. 5. All references to the “Agreement” in the Original Agreement, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, and this Amendment No. 6 shall mean the Original Agreement as amended hereby.

2.Amendments

2.1 Exhibit A, Section A1.1 (Licensed Patents). After the end of the table listing Licensed Patents[***] in Exhibit A, Section A1.1 of the Original Agreement, the following is hereby inserted:

Amendment 6 to Exclusive License between Sana Biotechnology, Inc. and University of Washington

UW CoMotion [***]Page 1 of 2



Exhibit 10.4

CONFIDENTIAL

[***]

3.Miscellaneous.

3.1Amendment Fee.  Company will pay University a one-time fee of [***] US Dollars ($[***]) in consideration for the additional rights granted to Company under this Third Amendment, payable within [***] days of the Amendment No. 6 Effective Date.

3.2Effect and Interpretation.  This Amendment No. 6 shall be effective for all purposes as of the Amendment No. 6 Effective Date.  To the extent that there are any inconsistencies between this Amendment No. 5 and the Original Agreement as amended by Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, and Amendment No. 5, the terms of this Amendment No. 6 shall supersede those set forth in the Original Agreement, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, and Amendment No. 5.  Except as otherwise expressly modified by this Amendment No. 6, the Original Agreement as amended by Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, and Amendment No. 5 shall remain in full force and effect in accordance with its terms.  As of the Amendment No. 6 Effective Date, the term “Agreement” (as used herein and in the Original Agreement, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4 and Amendment No. 5) shall mean the Original Agreement, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, and Amendment No. 5 as amended by this Amendment No. 6.

3.3Counterparts.  This Amendment No. 6 may be executed in one or more counterparts by original, facsimile or PDF signature, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, COMPANY and UNIVERSITY have caused this Amendment No. 6 to be executed by their respective duly authorized representatives as of the Amendment No. 6 Effective Date.

 


	
SANA BIOTECHNOLOGY, INC.
	
 
	
UNIVERSITY OF WASHINGTON

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
By:
	
/s/ Chris Pritchard
	
 
	
By:
	
/s/ Fiona Wills

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
Name:
	
Chris Pritchard
	
 
	
Name:
	
Fiona Wills

	
 
	
 
	
 
	
 
	
 

	
Title:
	
VP, Business Development
	
 
	
Title:
	
Associate Vice Provost

	
 
	
 
	
 
	
 
	
 

	
Date:
	
03/11/2021
	
 
	
Date:
	
03/11/2021




 

Amendment 6 to Exclusive License between Sana Biotechnology, Inc. and University of Washington

UW CoMotion [***]Page 2 of 2